Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.
作者信息
Tan E M
机构信息
The Scripps Research Institute, MEM131, 10550 N. Torrey Pines Road, La Jolla, California 92037, USA.
出版信息
J Clin Invest. 2001 Nov;108(10):1411-5. doi: 10.1172/JCI14451.
Abstract
摘要
相似文献
1
Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.
J Clin Invest. 2001 Nov;108(10):1411-5. doi: 10.1172/JCI14451.
2
Antibodies as oncogenes: a hypothesis.
Med Hypotheses. 2006;67(3):471-3. doi: 10.1016/j.mehy.2006.03.006. Epub 2006 Apr 24.
3
[p53 mutations and their role in tumorigenesis].
Tanpakushitsu Kakusan Koso. 1997 Jul;42(10 Suppl):1567-75.
4
Immunological aspects of the autonomous behaviour of tumours.
Biomed Sci. 1990;1(6):565-70.
5
The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs.
RNA Biol. 2011 Sep-Oct;8(5):817-28. doi: 10.4161/rna.8.5.16041. Epub 2011 Sep 1.
6
[Pdcd4 tumor suppressor: properties, functions, and their application to oncology].
Mol Gen Mikrobiol Virusol. 2010(2):3-11.
7
p53 mutation heterogeneity in cancer.
Biochem Biophys Res Commun. 2005 Jun 10;331(3):834-42. doi: 10.1016/j.bbrc.2005.03.190.
8
The p53 tumour suppressor gene.
Nature. 1991 Jun 6;351(6326):453-6. doi: 10.1038/351453a0.
9
Methylation, mutation and cancer.
Bioessays. 1992 Jan;14(1):33-6. doi: 10.1002/bies.950140107.
10
Oncogenes and tumor suppressor genes as paradigms in oncogenesis.
J BUON. 2007 Sep;12 Suppl 1:S9-12.
引用本文的文献
1
The diagnostic efficacy of seven autoantibodies in early detection of ground-glass nodular lung adenocarcinoma.
Front Oncol. 2024 Nov 26;14:1499140. doi: 10.3389/fonc.2024.1499140. eCollection 2024.
2
Development and validation of a TAAbs and TAAs based non-invasive model for diagnosing lung cancer.
Heliyon. 2024 Jun 29;10(13):e33888. doi: 10.1016/j.heliyon.2024.e33888. eCollection 2024 Jul 15.
3
Eng Meng Tan.
Ann Rheum Dis. 2024 Sep 30;83(10):1256-1259. doi: 10.1136/ard-2024-226025.
4
High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia.
Cancers (Basel). 2024 Feb 22;16(5):884. doi: 10.3390/cancers16050884.
5
Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies.
Front Immunol. 2024 Jan 22;15:1343020. doi: 10.3389/fimmu.2024.1343020. eCollection 2024.
6
Immunoseroproteomic profiling in autoantibody to ENO1 as potential biomarker in immunodiagnosis of osteosarcoma by serological proteome analysis (SERPA) approach.
Oncoimmunology. 2021 Sep 24;10(1):1966969. doi: 10.1080/2162402X.2021.1966969. eCollection 2021.
7
Identification of novel tumor-associated antigens and evaluation of a panel of autoantibodies in detecting oral cancer.
BMC Cancer. 2023 Aug 28;23(1):802. doi: 10.1186/s12885-023-11247-w.
8
From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer.
Front Genet. 2023 Feb 24;14:1110656. doi: 10.3389/fgene.2023.1110656. eCollection 2023.
9
Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab.
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-005848.
10
Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs.
Int J Mol Sci. 2023 Jan 28;24(3):2505. doi: 10.3390/ijms24032505.
本文引用的文献
1
Interplay between genetics and the environment in the development of celiac disease: perspectives for a healthy life.
J Clin Invest. 2001 Nov;108(9):1261-6. doi: 10.1172/JCI14344.
2
Thyroid autoimmunity.
J Clin Invest. 2001 Nov;108(9):1253-9. doi: 10.1172/JCI14321.
3
Autoimmune type 1 diabetes: resolved and unresolved issues.
J Clin Invest. 2001 Nov;108(9):1247-52. doi: 10.1172/JCI14257.
4
Transcription activating property of autoantigen SG2NA and modulating effect of WD-40 repeats.
Exp Cell Res. 2001 Oct 1;269(2):312-21. doi: 10.1006/excr.2001.5320.
5
Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
Am J Pathol. 2001 Sep;159(3):945-53. doi: 10.1016/S0002-9440(10)61770-1.
6
De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma.
Clin Exp Immunol. 2001 Jul;125(1):3-9. doi: 10.1046/j.1365-2249.2001.01585.x.
7
Surfing the p53 network.
Nature. 2000 Nov 16;408(6810):307-10. doi: 10.1038/35042675.
8
Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
Br J Cancer. 2000 Nov;83(10):1338-43. doi: 10.1054/bjoc.2000.1446.
9
What is missing in immunology to understand immunity?
Nat Immunol. 2000 Sep;1(3):181-5. doi: 10.1038/79712.
10
Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein.
Cancer Res. 2000 Jun 1;60(11):2756-9.
Zotero 插件